About
PolTREG develops advanced cell therapies using engineered regulatory T cells (Tregs) for autoimmune diseases such as Type-1 Diabetes, Multiple Sclerosis, and ALS, aiming to provide disease-modifying treatments.
Explore PolTREG's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.